Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?

Detalles Bibliográficos
Autores principales: Kanemura, Hiroaki, Takeda, Masayuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481636/
https://www.ncbi.nlm.nih.gov/pubmed/32953535
http://dx.doi.org/10.21037/tlcr-20-707
_version_ 1783580648602075136
author Kanemura, Hiroaki
Takeda, Masayuki
Nakagawa, Kazuhiko
author_facet Kanemura, Hiroaki
Takeda, Masayuki
Nakagawa, Kazuhiko
author_sort Kanemura, Hiroaki
collection PubMed
description
format Online
Article
Text
id pubmed-7481636
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-74816362020-09-17 Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy? Kanemura, Hiroaki Takeda, Masayuki Nakagawa, Kazuhiko Transl Lung Cancer Res Editorial Commentary AME Publishing Company 2020-08 /pmc/articles/PMC7481636/ /pubmed/32953535 http://dx.doi.org/10.21037/tlcr-20-707 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Kanemura, Hiroaki
Takeda, Masayuki
Nakagawa, Kazuhiko
Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
title Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
title_full Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
title_fullStr Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
title_full_unstemmed Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
title_short Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
title_sort simultaneous targeting of met overexpression in egfr mutation-positive non-small cell lung cancer can increase the benefit of egfr-tki therapy?
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481636/
https://www.ncbi.nlm.nih.gov/pubmed/32953535
http://dx.doi.org/10.21037/tlcr-20-707
work_keys_str_mv AT kanemurahiroaki simultaneoustargetingofmetoverexpressioninegfrmutationpositivenonsmallcelllungcancercanincreasethebenefitofegfrtkitherapy
AT takedamasayuki simultaneoustargetingofmetoverexpressioninegfrmutationpositivenonsmallcelllungcancercanincreasethebenefitofegfrtkitherapy
AT nakagawakazuhiko simultaneoustargetingofmetoverexpressioninegfrmutationpositivenonsmallcelllungcancercanincreasethebenefitofegfrtkitherapy

Ejemplares similares